昂利康(002940.SZ)與海昶生物就"HC008"簽訂合作備忘錄
格隆匯5月30日丨昂利康(002940.SZ)公佈,2021 年 5 月 28 日,公司與浙江海昶生物醫藥技術有限公司(以下簡稱"海昶生物",合稱"雙方"或"交易雙方")就"HC008"(以下簡稱"標的藥品",一款酰胺類局部麻醉藥的複雜注射劑仿製藥,尚處於研發階段)的合作開發項目及成立合資公司簽訂《海昶生物與昂利康關於"HC008"合作項目之合作備忘錄》(以下簡稱"合作備忘錄"),此次簽訂的合作備忘錄僅作為推進此次合作的框架性、意向性協議,有關具體合作內容尚待簽訂正式相關合同予以明確。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.